backtop


Print 11 comment(s) - last by Lugaidster.. on Dec 9 at 10:01 AM


Edward R. Biehl, co-discoverer of the HSB-13 compound  (Source: vvoice.vo.llnwd.net)
HSB-13 compound could halt diseases like Alzheimer's, Huntington's and Parkinson's

Southern Methodist University (SMU) and University of Texas at Dallas researchers have found hope for those suffering from diseases like Alzheimer's, Parkinson's and Huntington's through the discovery of a group of molecules which could help protect the brain.

Edward R. Biehl, study leader and a synthetic organic chemist at SMU, and Santosh R. D'Mello, co-author of the study and a biology professor at UT Dallas, have developed the compounds in an effort to halt the onset of nerve-degenerative diseases and relieve symptoms. 

Alzheimer's, Parkinson's and and Huntington's are neurodegenerative diseases in the central nervous system, and afflict more than five million Americans (mainly senior citizens). These diseases are caused by the immoderate loss of neurons in an area of the mid-brain, which leads to a decline in motor skills, such as walking and speaking, as well as memory loss and behavior problems. 

Previous treatments cannot halt or reverse these types of nerve-degenerative diseases. They only relieve symptoms, and sometimes even fail at that due to the severe side effects of these medications. 

But now, Biehl and D'Mello have worked together to develop compounds that could potentially protect the brain from nerve-degenerative diseases. They came upon this discovery when developing synthetic chemicals that contained a class of heterocyclic organic compounds. One particular compound in the heterocyclic class proved to be protective of neurons in tissue culture models. Furthermore, this same compound, named HSB-13, has also proven to be effective in fighting neurodegenerative diseases in animal models. 

"Our compounds protect against neurodegeneration in mice," said Biehl. "Given successful development of the compounds into drug therapies, they would serve as an effective treatment for patients with degenerative brain diseases."

HSB-13 not only decreased degeneration in the forebrain, but also corrected behavioral problems. It has also proved to be nontoxic while remaining "extremely potent."

Biotechnology and therapeutics company EncephRx, which is based in Dallas, is looking to create drug therapies based on this new class of compounds. The company was granted worldwide license to the "jointly owned compounds," and when the research is complete, EncephRx's pharmaceuticals made of these small compounds will be the first therapeutic tools capable of protecting brain cells and keeping them from dying. 

"Additional research needs to be done, but these compounds have the potential for stopping or slowing the relentless loss of brain cells in diseases such as Alzheimer's and Parkinson's," said D'Mello. "The protective effect that they display in tissue culture and animal models of neurodegenerative disease provides strong evidence of their promise as drugs to treat neurodegenerative disorders."



Comments     Threshold


This article is over a month old, voting and posting comments is disabled

By jimhsu on 12/9/2010 8:34:47 AM , Rating: 2
Theoretically we can test all of these things:

a. Detect protein binding via a FRET-like system (google FRET), yeast two-hybrid, GST pulldown, etc. If the small molecule makes elimination easier, you could also track the protein itself via renal or bile secretions. You could of course radiolabel the small molecule and trace where it goes.

b. Again, radiolabel it to see where it goes. Track metabolism and elimination. Determine if inhibition of the hypothetical neuron-small molecule interaction disrupts the efficacy.

Am I just nerdy, or is he holding a reagant bottle from Fisher Scientific (probably a salt of some kind) and standing behind a GC-FID readout with a solvent peak (probably ethanol or acetone or something of that sort)?


"We shipped it on Saturday. Then on Sunday, we rested." -- Steve Jobs on the iPad launch














botimage
Copyright 2014 DailyTech LLC. - RSS Feed | Advertise | About Us | Ethics | FAQ | Terms, Conditions & Privacy Information | Kristopher Kubicki